Ryan Basen recently published an article, “Beyond CBD, THC: ‘Minor’ Cannabinoids Flood Market,” in MEDPAGETODAY. In the article, Ryan Basen elaborated on the rise of consumer use of minor cannabinoids, specifically delta-8 THC, and the lack of scientific evidence. Ryan highlighted BioMedican‘s aim to produce CBG-based pharmaceutical products within a year.
After the CBD boom, the cannabis market observed a surge in three minor cannabinoids; cannabigerol (CBG), cannabinol (CBN), and delta-8 THC (tetrahydrocannabinol). Medical use of these minor cannabinoids has increased since last year. The efficacy and safety of these minor cannabinoids, especially delta-8 THC that captivated the cannabis market, is in question by practitioners and cannabis industry insiders.
Recently emerged delta-8 THC is a synthetic compound similar to delta-9 THC but has a negligible psychoactive effect. Delta-8 THC is captivating to those consumers who eschew CBD-based products. Current scarce data on delta-8 THC only authenticate its potential to activates CB1 and CB2 endocannabinoid system (ECS) receptors and reduced psychoactive potential than delta-9 THC. The safety and efficacy data of this compound in humans is negligible.
Minor cannabinoids are the fastest-growing sector of the cannabis industry. These compounds observed a boost after the legalization of hemp agriculture by the 2018 Farm Bill. Delta-8 THC alone made sales of at least $10 million last year, which depicts its potential to dominate the minor cannabinoid market. CBG, mother of all cannabinoids, and CBN have shown efficacy and safety on large-scale animal studies. Ryan Basen observed a boom in medical use (with cautions) of CBG and CBN-based products by practitioners. Expert says this boom is merely consumer-driven and lacks adequate human evidence.
BioMedican is leading the race of these minor cannabinoids production owing to its advanced production and research strategies. Our efficient biosynthetic platform holds enormous potential to meet booming minor cannabinoids market demand.
BioMedican is ready to produce its CBG-based pharmaceutical product within a year. We are inviting investors to participate in our advanced biosynthetic platform to get a faster return on investments.
